Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
6(85.7%)
Phase 3
1(14.3%)
7Total
Phase 1(6)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07438886Phase 1Not Yet Recruiting

Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers

Role: lead

NCT07179081Phase 1Recruiting

A Study of AL58805 in Patients With Advanced Tumors

Role: lead

NCT07132957Phase 1Completed

A Study of AL8326 in Healthy Subjects

Role: lead

NCT06247605Phase 3Recruiting

A Phase IIII Study of AL8326 in Small Cell Lung Cancer

Role: lead

NCT05486598Phase 1Unknown

A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects

Role: lead

NCT04890587Phase 1Unknown

A Phase I Study of AL8326 in Advanced Solid Tumor

Role: lead

NCT04890795Phase 1Unknown

A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer

Role: lead

All 7 trials loaded